文献速递肝病消化道肿瘤与早癌

甲羟戊酸通路通过CoQ10生成和硒代半胱氨酸-tRNA修饰抑制铁死亡促进肝癌

Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.
PubMed 文献 · J Hepatol · 2025-07-11

该研究探讨甲羟戊酸通路在肝细胞癌(HCC)中的作用,发现MVD在HCC组织中显著过表达,抑制MVD可降低IPP和CoQ10水平、抑制硒蛋白翻译并触发铁死亡。在小鼠模型中,6-FMEV和阿托伐他汀均有效抑制HCC肿瘤生长,与酪氨酸激酶抑制剂或抗PD-1免疫治疗联用显示协同抗肿瘤效果。

要点

  • MVD在HCC组织中显著过表达,抑制MVD可触发HCC细胞铁死亡。
  • 6-FMEV降低IPP和CoQ10水平并抑制硒蛋白翻译。
  • 阿托伐他汀和6-FMEV在小鼠模型中抑制HCC肿瘤生长。

核心结论

  • 甲羟戊酸通路通过CoQ10生成和硒蛋白翻译保护HCC细胞免于铁死亡。
  • 6-FMEV和阿托伐他汀的抗肿瘤作用支持靶向甲羟戊酸通路治疗HCC的潜力,可单用或与现有治疗联用。

研究设计与样本

  • 在人HCC样本中评估MVD表达的临床相关性。
  • 使用染色质免疫沉淀检查MVD调控,靶向代谢组学测量IPP和CoQ10水平,核糖体和多聚核糖体谱分析评估硒蛋白翻译。
  • 使用多种体外和体内HCC模型评估甲羟戊酸通路抑制剂的疗效。

主要发现

  • MVD在人HCC组织中显著过表达。
  • 6-FMEV药理学抑制MVD降低IPP和CoQ10水平,抑制硒蛋白翻译,并在HCC细胞中触发铁死亡。
  • TRSP或TRIT1的遗传消融同样阻断硒蛋白合成并诱导铁死亡。
  • 在小鼠模型中,6-FMEV和阿托伐他汀均有效抑制HCC肿瘤生长,包括脂肪性HCC。
  • 甲羟戊酸通路抑制与酪氨酸激酶抑制剂或抗PD-1免疫治疗联用显示协同抗肿瘤效果。

临床怎么用

  • 作者认为,靶向甲羟戊酸通路(单用或与现有治疗联用)具有治疗HCC的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ferroptosis has emerged as a promising therapeutic approach for hepatocellular carcinoma (HCC). To evade ferroptosis, HCC cells depend on the glutathione/GPX4 and CoQ10/FSP1 antioxidant systems. The mevalonate pathway enzyme mevalonate diphosphate decarboxylase (MVD) generates isopentenyl pyrophosphate (IPP), which supports both selenocysteine-tRNA modification and CoQ10 biosynthesis. Here, we investigated the role of the mevalonate pathway in HCC and explored novel vulnerabilities for therapeutic targeting. METHODS: The clinical relevance of MVD expression was assessed in human HCC samples. Regulation of MVD was examined using chromatin immunoprecipitation. Targeted metabolomics was performed to measure IPP and CoQ10 levels. Selenoprotein translation was evaluated via ribosome and polysome profiling. Multiple in vitro and in vivo HCC models were used to assess the efficacy of mevalonate pathway inhibitors. RESULTS: MVD was significantly overexpressed in human HCC tissues. Pharmacological inhibition of MVD using 6-FMEV reduced levels of IPP and CoQ10, suppressed selenoprotein translation, and triggered ferroptosis in HCC cells. Genetic ablation of TRSP (which encodes selenocysteine-tRNA) or TRIT1 (responsible for i6A tRNA modification) similarly blocked selenoprotein synthesis and induced ferroptosis. In mouse models, both 6-FMEV and atorvastatin (a clinically approved upstream mevalonate pathway inhibitor) effectively suppressed HCC tumor growth, including steatotic HCC. Moreover, mevalonate pathway inhibition showed synergistic anti-tumor effects when combined with either tyrosine kinase inhibitors or anti-PD-1 immunotherapy. CONCLUSIONS: Our findings reveal a critical link between the mevalonate pathway, CoQ10 production, and selenoprotein translation in protecting HCC cells from ferroptosis. The demonstrated anti-tumor role of 6-FMEV and atorvastatin supports the therapeutic potential of targeting the mevalonate pathway in HCC, either alone or in combination with existing treatments. IMPACT AND IMPLICATIONS: Current therapies show limited efficacy for advanced hepatocellular carcinoma (HCC). This study demonstrates that targeting the mevalonate pathway induces ferroptosis in HCC by disrupting CoQ10 biosynthesis and selenoprotein translation. Clinically relevant inhibitors, such as atorvastatin and the MVD inhibitor 6-FMEV, effectively suppressed tumor growth across multiple HCC subtypes in preclinical models. Furthermore, combining mevalonate pathway inhibitors with tyrosine kinase inhibitors or immune checkpoint inhibitors enhanced anti-tumor efficacy. These findings underscore the translational potential of mevalonate pathway inhibition as a novel therapeutic strategy for HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Lee D, Kwan KK, et al. Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. J Hepatol. 2025. PMID: 40653112. doi:10.1016/j.jhep.2025.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。